Benthopanope indica (De Man, 1887) was originally described from the Mergui Archipelago and has subsequently been reported from many Indo-West Pacific localities. The identity of this species is herein clarified. The re-examination of the type female, fresh specimens collected from Chilika Lake, Odisha State, India, as well as material from other locations, revealed that B. indica is not a Benthopanope species but should be assigned to Pilumnopeus instead. Pilumnopeus indicus comb. nov. is now restricted to the Indian Ocean and is reported from the western coast of Peninsular Malaysia for the first time. Heteropanope pearsei Rathbun, 1932, described from East Asia, previously synonymised under P. indicus by Sakai (1965), is here shown to be valid species of Pilumnopeus, and all previous records of "B. indica" from Japan, China, Taiwan, and Korea must be referred to this species. The two species can be differentiated by characters of the carapace, epistome, chelipeds and gonopods. Lectotypes are also designated for both species.
Recent studies indicate relatively high international rates of adjunctive psychotropic medication, including mood stabilizers, for patients with schizophrenia. Since such treatments are little studied in Asia, we examined the frequency of mood-stabilizer use and its clinical correlates among hospitalized Asian patients diagnosed with schizophrenia in 2001-2008. We evaluated usage rates of mood stabilizers with antipsychotic drugs, and associated factors, for in-patients diagnosed with DSM-IV schizophrenia in 2001, 2004 and 2008 in nine Asian regions: China, Hong Kong, India, Korea, Japan, Malaysia, Taiwan, Thailand, and Singapore. Overall, mood stabilizers were given to 20.4% (n=1377/6761) of hospitalized schizophrenia patients, with increased usage over time. Mood-stabilizer use was significantly and independently associated in multivariate logistic modeling with: aggressive behaviour, disorganized speech, year sampled (2008 vs. earlier), multiple hospitalizations, less negative symptoms, younger age, with regional variation (Japan, Hong Kong, Singapore>Taiwan or China). Co-prescription of adjunctive mood stabilizers with antipsychotics for hospitalized Asian schizophrenia patients increased over the past decade, and was associated with specific clinical characteristics. This practice parallels findings in other countries and illustrates ongoing tension between evidence-based practice vs. individualized, empirical treatment of psychotic disorders.